Anson Funds Management LP Aeterna Zentaris Inc. Transaction History

Anson Funds Management LP

  • $839 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019
SELL
$3.03 - $4.65 $1.02 Million - $1.56 Million
-335,781 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$1.3 - $3.87 $436,515 - $1.3 Million
335,781 New
335,781 $987,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Anson Funds Management LP Portfolio

Follow Anson Funds Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anson Funds Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Anson Funds Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email